Evidence map›Paper›PMID 38568225›Full record

ArticleJournal of neurology2024

Pregnancy effect on disease activity in women with multiple sclerosis treated with cladribine.

E Signoriello, M Foschi, R Lanzillo, J Frau, E Cocco, G Borriello, A Ianniello, M Trotta, D Landi, G T Maniscalco and 9 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Cladribine tablets in the new multiple sclerosis era.Therapeutic advances in neurological disorders · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 13 institutions in 1 country.

E SignorielloMultiple Sclerosis Center, Second Division of Neurology, Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, Naples, Italy.
M FoschiDepartment of Neuroscience, MS Center-Neurology Unit, S. Maria Delle Croci Hospital, AUSL Romagna, Ravenna, Italy.
R LanzilloDepartment of Neurosciences, Reproductive and Odontostomatological Sciences, Federico II University, Naples, Italy.
J FrauMultiple Sclerosis Center, Department of Medical Sciences and Public Health University of Cagliari, Binaghi Hospital Cagliari/Italy, Cagliari, Italy.
E CoccoMultiple Sclerosis Center, Department of Medical Sciences and Public Health University of Cagliari, Binaghi Hospital Cagliari/Italy, Cagliari, Italy.
G BorrielloSan Pietro Fatebenefratelli-Hospital-MS Center Rome, Rome, Italy.
A IannielloDepartment of Human Neuroscience, Sapienza University of Rome, Rome, Italy.
M TrottaUnit of Neurology A.O. Annunziata, Cosenza, Italy.
D LandiMultiple Sclerosis Clinical and Research Unit, Department of Systems Medicine, University of Rome Tor Vergata, Tor VergataUniveristy Hospital, Rome, Italy.
G T ManiscalcoNeurological Clinic and Multiple Sclerosis Center, A Cardarelli Hospital, Naples, Italy.
F RuscicaU.O.C. Neurologia E Centro SMFondazione Istituto G. Giglio, Cefalù, PA, Italy.
S ToscanoDepartment "GF Ingrassia", Section of Neurosciences, University of Catania, Catania, Italy.
F PattiDepartment "GF Ingrassia", Section of Neurosciences, University of Catania, Catania, Italy.
A ZanghìDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
E D'AmicoDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
R FantozziUnit of Neurology, IRCCS Neuromed, Pozzilli, IS, Italy.
D CentonzeUnit of Neurology, IRCCS Neuromed, Pozzilli, IS, Italy.
G LusMultiple Sclerosis Center, Second Division of Neurology, Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, Naples, Italy.
S BonavitaMultiple Sclerosis Center, Second Division of Neurology, Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, Naples, Italy. simona.bonavita@unicampania.it.ORCID http://orcid.org/0000-0002-8561-9720
University of Campania "Luigi Vanvitelli" · ITIstituto Neurologico Mediterraneo · ITUniversity of Cagliari · ITUniversity of Catania · ITUniversity of Foggia · ITFatebenefratelli Hospital · ITFederico II University Hospital · ITFondazione Istituto G. Giglio di Cefalù · ITOspedale Annunziata di Cosenza · ITOspedale Antonio Cardarelli · ITSapienza University of Rome · ITUniversity of L'Aquila · ITUniversity of Rome Tor Vergata · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCladribine is an oral immune reconstitution therapy for relapsing multiple sclerosis (RMS). Hormonal and immune changes are responsible for the decline of disease activity in the third trimester of pregnancy and disease reactivation in the early post-partum period.We investigate the impact of pregnancy on disease activity in women with MS who conceived after cladribine treatment.

methodsWe recruited women of childbearing age with relapsing-remitting MS (RRMS) who became pregnant or not after being treated with cladribine. For both groups, demographic, clinical and radiological data were collected 1 year before and after treatment during a mean follow-up of 3.53 years. We compared disease activity over time between groups using variance analysis for repeated measures.

results48 childbearing women were included. 25 women had a pregnancy after a mean of 1.75 years from the first treatment cycle. Women with or without pregnancy did not differ in demographics or pre-cladribine disease activity. No significant differences in disease activity or EDSS worsening were found between women with or without pregnancy. DISCUSSION: Our findings suggest that pregnancy does not appear to influence disease activity and disability in women previously treated with cladribine; further studies with larger numbers and longer follow-up are needed to confirm this finding.

Indexed as

CladribineImmunosuppressive AgentsMultiple Sclerosis, Relapsing-RemittingAdultDisability EvaluationFemaleFollow-Up StudiesHumansPregnancyPregnancy ComplicationsYoung AdultCladribineImmunosuppressive AgentsBreastfeedingCladribineDisease activityMultiple sclerosisPregnancy

Identifiers

PMID38568225
PMCPMC11233318
OpenAlexW4393854181

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.